[1]眭瑞卿,朱超林.从肿瘤精准医疗创新性临床试验探讨中医辨证论治科学性[J].中国中医药信息杂志,2019,26(4):1-4.[doi:10.3969/j.issn.1005-5304.2019.04.001]
 SUI Ruiqing,ZHU Chaolin.Discussion on Scientificalness of TCM Syndrome Differentiation and Treatment Based on Innovative Clinical Trials of Tumor Precision Medicine[J].zhongguo zhongyiyao xinxi zazhi,2019,26(4):1-4.[doi:10.3969/j.issn.1005-5304.2019.04.001]
点击复制

从肿瘤精准医疗创新性临床试验探讨中医辨证论治科学性

参考文献/References:

[1] 《胃肠病学和肝病学杂志》编辑部.2017年国家启动“精准医学计划”[J].胃肠病学和肝病学杂志,2017,26(1):7-16.
[2] 邵小钧,席庆.精准医疗——肿瘤诊治的新模式[J].现代肿瘤医学, 2016,24(4):675-677.
[3] KRETZLER M, SEDOR J R. Introduction:Precision medicine for glomerulardisease:The road forward[J]. Semin Nephrol,2015,35(3):209-211.
[4] KLAUSCHEN F, ANDREEFF M, KEILHOLZ U, et al. The combinatorial complexity of cancer precision medicine[J]. Oncoscience,2014, 1(7):504-509.
[5] 吴一龙.精准癌医学:走向未来的路[J].循证医学,2015, 15(1):1-2.
[6] 梅志刚,谭凌菁.从辨证论治看中医在我国精准医疗计划中的作为[J].中华中医药杂志,2016,31(10):3887-3890.
[7] 俞悦,周爱萍,曾益新.HER2阳性胃癌的治疗研究进展[J].中国肿瘤临床,2017,44(2):59-63.
[8] 王绍钧,王锐,朱冬波.实体瘤靶向药物的研究进展[J].中国药房, 2017,28(8):1149-1152.
[9] HYMAN D M, PUZANOV I, SUBBIAH V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations[J]. New England Journal of Medicine,2015,373(8):726-736.
[10] National Cancer Institute. Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors, lymphomas, or multiple myeloma (The MATCH Screening Trial)[EB/OL].(2015-06-08)[2017-07-17].https://www.clinicaltrials. gov/ct2/show/NCT02465060?cond=NCT02465060&rank=1.html.
[11] 陆兵.Ⅳ期肺腺癌初治患者的中医证型及临床特点分析[D].北京:北京中医药大学,2011.(收稿日期:2017-10-11)(修回日期:2018-11-21;编辑:梅智胜)

备注/Memo

基金项目:第四批全国中医优秀人才研修项目(2017年);全国名老中医药专家传承工作室建设项目(2011年)通讯作者:朱超林,E-mail:zhu_chaolin@sina.com

更新日期/Last Update:

2019-04-01